Accepted Manuscript

Dissecting aggressive B-cell lymphoma through genomic analysis – What is clinically relevant?

David W. Scott, MBChB PhD, Lisa M. Rimsza, MD

PII: \$1521-6926(18)30041-0

DOI: 10.1016/j.beha.2018.07.003

Reference: YBEHA 1032

To appear in: Best Practice & Research Clinical Haematology

Received Date: 23 May 2018
Revised Date: 21 June 2018
Accepted Date: 2 July 2018

Please cite this article as: Scott DW, Rimsza LM, Dissecting aggressive B-cell lymphoma through genomic analysis – What is clinically relevant?, *Best Practice & Research Clinical Haematology* (2018), doi: 10.1016/j.beha.2018.07.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Title: Dissecting aggressive B-cell lymphoma through genomic analysis – What is clinically relevant?

Authors: David W. Scott, MBChB PhD1,2 and Lisa M. Rimsza, MD3

Affiliations:

- Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
- 2. Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
- 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona, USA

Corresponding Author:

David W. Scott, MBChB, PhD BC Cancer Research Centre, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada Email: dscott8@bccancer.bc.ca

Underlining indicates words that are to be italicized.

Download English Version:

https://daneshyari.com/en/article/10157422

Download Persian Version:

 $\underline{https://daneshyari.com/article/10157422}$

Daneshyari.com